CSL expects regulatory objection to Talecris bid

Courtesy Newsvine - business  Mon, 05/25/2009 - 15:35

Australian vaccines and blood products developer CSL Ltd. said Monday that the U.S. Federal Trade Commission is likely to block its proposed $3.1 billion acquisition of rival Talecris Biotherapeutics Inc.


 

Related items

For $2 a Star, a Retailer Gets 5-Star Reviews
Agencies like the Federal Trade Commission have been trying to crack down on online product reviews that do not disclose the connection between a merchant and the person doling out the...

China prepares for big entry into vaccine market
The world should get ready for a new Made in China product — vaccines.

Reebok to Pay $25 Million Over Toning Shoe Claims
The Federal Trade Commission said the sportswear maker agreed to pay $25 million to settle allegations of unfounded claims about the health benefits of two lines of shoes.

Samsung SCX-4200 3-in-1 True Multifunction Printer
The SCX-4200 Digital Productivity Center is a low cost black and white laser printer, delivering 3 in 1 true multifunction performance with professional laser output.Keep your valuable real...

BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
The X5 Stereo Bluetooth Headset is a portable multi-function device utilizing the latest cutting edge technologies allowing you to stream high quality music and make voice calls using a...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com